Zanubrutinib

Evidence Level: L5

Predicted Indications: 6

Zanubrutinib

Pharmacist Assessment Report

Zanubrutinib: From Mantle Cell Lymphoma to Myeloid Leukemia

One-Sentence Summary

Zanubrutinib is a BTK inhibitor originally used for B-cell malignancies such as mantle cell lymphoma. The TxGNN model predicts it may be effective for myeloid leukemia, but this is mainly a computational prediction. Only 1 clinical trial (Phase 1, where zanubrutinib is a combination partner) and 10 publications, mostly about B-cell diseases, are linked to it, so direct supporting evidence is very limited.

Quick Overview

Item	Content
Original Indication	Mantle cell lymphoma, B-cell neoplasm, lymphosarcoma
Predicted New Indication	Myeloid leukemia
TxGNN Prediction Score	0.9965
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, zanubrutinib is a next-generation Bruton tyrosine kinase (BTK) inhibitor. Its efficacy in B-cell malignancies has been established, and the data compiled for this report suggest that it may be mechanistically relevant to other blood cancers.

The link to myeloid leukemia is indirect. BTK is expressed in some myeloid cells and AML blasts and may contribute to survival signaling. However, there is no direct clinical evidence of benefit. The publications compiled for this report concern chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia and BTK inhibitor safety. These are all B-cell diseases, not myeloid leukemia. The high score (0.9965) should be read as a model prediction, not as proof of efficacy.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05665530	Phase 1	Completed	86	Safety and efficacy of PRT2527 (a CDK9 inhibitor) alone and combined with zanubrutinib or venetoclax in relapsed/refractory hematologic malignancies. Zanubrutinib is only a combination partner, probably in a B-cell cohort, so this is not direct evidence in myeloid leukemia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39647999	2025	RCT	J Clin Oncol	SEQUOIA phase 3, 5-year follow-up: zanubrutinib vs bendamustine + rituximab in treatment-naïve CLL/SLL
36400069	2023	Cohort	Lancet Haematol	Phase 2 single-arm study in B-cell malignancy patients intolerant of earlier BTK inhibitors
40334067	2025	Cohort	Blood Adv	Updated results: zanubrutinib well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib
40829104	2026	Cohort	Blood Adv	Pooled analysis across studies in CLL/SLL with del(17p) and/or TP53 mutations (N = 301)
34959482	2021	Review	Pharmaceutics	Tyrosine kinase inhibitors in chronic leukemias (CML and CLL)
36402930	2023	Review	Leukemia	Managing Waldenström macroglobulinemia with BTK inhibitors
37150651	2023	Review	Clin Lymphoma Myeloma Leuk	Hepatitis B virus reactivation in patients receiving BTK inhibitors
42192981	2026	Review	Cancers	BTK inhibitors in CLL: hypogammaglobulinemia and infection risk
38288815	2024	Review	Anti-Cancer Agents Med Chem	Synthetic methods of FDA-approved anticancer drugs (2018–2021)
36325357	2022	Case report	Front Immunol	Rare coexistence of Waldenström macroglobulinemia and B-cell ALL

None of these studies tests zanubrutinib in myeloid leukemia.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02512963	BRUKINSA	Not specified	Not specified
02554267	BRUKINSA	Not specified	Not specified

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (BTK inhibitor), not a conventional cytotoxic agent
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions. Complete blood count and liver function are commonly monitored for oncology drugs of this type.
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: The interaction screening returned 100 interacting drugs. Major-level examples include aprepitant, acetylsalicylic acid, dexamethasone, clarithromycin, cobicistat, deferasirox, deferiprone, samarium (153Sm) lexidronam, ibritumomab tiuxetan and tositumomab (I-131). Moderate-level examples include cimetidine, miconazole, clotrimazole, fenfluramine, sibutramine and troglitazone.
Other safety signals from the literature: Reports describe hepatitis B virus reactivation in patients on BTK inhibitors, and hypogammaglobulinemia with increased infection risk.

Package insert warnings and contraindications were not available for this report, so please refer to the package insert for them.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests mainly on the model score. The only linked trial is a Phase 1 combination study with no direct myeloid leukemia data, and the literature concerns B-cell diseases. Evidence level is L4, and the mechanistic link to myeloid leukemia is indirect.

To proceed, the following is needed:

Mechanism of action data and a clearer analysis of BTK dependence in myeloid leukemia (AML)
Preclinical studies or clinical data on zanubrutinib in myeloid leukemia
Verification of the actual cohort composition of NCT05665530
Package insert warnings and contraindications from Health Canada, which are required before safety screening
Approved indication and dosage form details for the two Canadian DINs
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.